Sanofi stock rating reiterated by Leerink after mixed amlitelimab results
Leerink has reiterated its stock rating for Sanofi following mixed results from the amlitelimab trials. Investors are watching closely as the pharmaceutical company navigates these developments.
WPN Brief
Leerink has reiterated its stock rating for Sanofi following mixed results from the amlitelimab trials. Investors are watching closely as the pharmaceutical company navigates these developments.
Ask WPN AI